22,237 reports of this reaction
3.2% of all TOCILIZUMAB reports
#2 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #2 most commonly reported adverse reaction for TOCILIZUMAB, manufactured by Genentech, Inc.. There are 22,237 FDA adverse event reports linking TOCILIZUMAB to RHEUMATOID ARTHRITIS. This represents approximately 3.2% of all 689,384 adverse event reports for this drug.
TOCILIZUMAB has an overall safety score of 85 out of 100. Patients taking TOCILIZUMAB who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is moderately reported among TOCILIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for TOCILIZUMAB:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 22,237 FDA reports for TOCILIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 3.2% of all adverse event reports for TOCILIZUMAB, making it one of the most commonly reported side effect.
If you experience rheumatoid arthritis while taking TOCILIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.